Kuros Biosciences signed a private label agreement to supply bone graft material to SeaSpine, which will market the products as OsteoCurrent in the U.S. and select markets in Europe, South America and the Middle East following regulatory approvals. Initial sales in the U.S. are slated to begin in 1H19.
Kuros’ proprietary synthetic bone graft technology comprises biphasic calcium phosphate with submicron surface topography that has an osteoinductive claim in Europe.
Kuros Biosciences signed a private label agreement to supply bone graft material to SeaSpine, which will market the products as OsteoCurrent in the U.S. and select markets in Europe, South America and the Middle East following regulatory approvals. Initial sales in the U.S. are slated to begin in 1H19.
Kuros’ proprietary synthetic bone graft...
Kuros Biosciences signed a private label agreement to supply bone graft material to SeaSpine, which will market the products as OsteoCurrent in the U.S. and select markets in Europe, South America and the Middle East following regulatory approvals. Initial sales in the U.S. are slated to begin in 1H19.
Kuros’ proprietary synthetic bone graft technology comprises biphasic calcium phosphate with submicron surface topography that has an osteoinductive claim in Europe.
Copy to clipboard 
